Portal is enabling smart syringes with a suite of next-generation digital drug delivery technologies developed from MIT research. Our devices are designed to enable pharma partner companies to transform their injectable biological drugs such as GLP-1s into therapies for the 21st century. We offer reusable, cloud-connected solutions that sidestep traditional needles and reduce the environmental burden of traditional single-use auto-injectors. Portal’s mission goes beyond merely enhancing the patient experience; it aims to assist biopharmaceutical partners in improving patient adherence and persistence to their treatments, thereby enhancing overall health outcomes and the return on investment for their biologics drug franchises. Portal’s technologies represent a significant step in redefining patient care and pharmaceutical innovation. Portal is currently raising a financing and looking to connect with investors at BIO.